Shanghai, China – October 9, 2025 – Medicilon is proud to announce that it has officially obtained certification of compliance with OECD Good Laboratory Practice (GLP) standards from Hungary, a member country of the Organization for Economic Co-operation and Development (OECD). This achievement marks another important milestone in Medicilon’s continuous pursuit of international quality excellence, following its OECD GLP certification from Mexico, further enhancing the company’s global regulatory credibility and competitiveness in pharmaceutical R&D services.

As part of its ongoing globalization strategy, Medicilon has made significant strides in strengthening its quality management system. Since 2025, the company’s newly established laboratories have successfully passed the NMPA GLP expansion certification and have undergone inspections and verifications by multiple international regulatory authorities, including the U.S. FDA and Japan’s PMDA. Together, these accreditations form a robust, multi-regional compliance framework that covers key pharmaceutical markets across China, the United States, Europe, and Japan.

The consecutive OECD GLP recognitions from both Hungary and Mexico underscore Medicilon’s long-standing commitment to adhering to international quality management standards and reflect the trust and recognition it has earned from the global scientific and regulatory community.

Looking ahead, Medicilon will continue to uphold international quality benchmarks while expanding and deepening its integrated, one-stop preclinical R&D service platform. By maintaining its focus on scientific rigor and operational excellence, Medicilon remains dedicated to accelerating the global development of innovative therapeutics and supporting clients in achieving successful international regulatory submissions.